1. Long-circulating XTEN864-annexin A5 fusion protein for phosphatidylserine-related therapeutic applications
- Author
-
Lena Ascher, Eyk Schellenberger, Karolina Garczynska, Akvile Haeckel, Jing Guo, Nicola Beindorff, and Sonal Prasad
- Subjects
Cancer Research ,Biodistribution ,Clinical Biochemistry ,Pharmaceutical Science ,Apoptosis ,Spleen ,Phosphatidylserines ,Article ,Flow cytometry ,Mice ,chemistry.chemical_compound ,Inflammatory cytokine storm ,Escherichia coli ,medicine ,Animals ,Apoptotic mimicry ,Tissue Distribution ,Mass cytometry ,Annexin A5 ,Programmed cell death ,Cancer ,Inflammation ,Pharmacology ,biology ,medicine.diagnostic_test ,Biochemistry (medical) ,Cell Biology ,Phosphatidylserine ,Atherosclerosis ,Molecular biology ,Fusion protein ,medicine.anatomical_structure ,chemistry ,biology.protein ,Antibody ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit - Abstract
Annexin A5 (anxA5) is a marker for apoptosis, but has also therapeutic potential in cardiovascular diseases, cancer, and, due to apoptotic mimicry, against dangerous viruses, which is limited by the short blood circulation. An 864-amino-acid XTEN polypeptide was fused to anxA5. XTEN864-anxA5 was expressed in Escherichia coli and purified using XTEN as tag. XTEN864-anxA5 was coupled with DTPA and indium-111. After intravenous or subcutaneous injection of 111In-XTEN864-anxA5, mouse blood samples were collected for blood half-life determination and organ samples for biodistribution using a gamma counter. XTEN864-anxA5 was labeled with 6S-IDCC to confirm binding to apoptotic cells using flow cytometry. To demonstrate targeting of atherosclerotic plaques, XTEN864-anxA5 was labeled with MeCAT(Ho) and administered intravenously to atherosclerotic ApoE−/− mice. MeCAT(Ho)-XTEN864-anxA5 was detected together with MeCAT(Tm)-MAC-2 macrophage antibodies by imaging mass cytometry (CyTOF) of aortic root sections. The ability of anxA5 to bind apoptotic cells was not affected by XTEN864. The blood half-life of XTEN864-anxA5 was 13 h in mice after IV injection, markedly longer than the 7-min half-life of anxA5. 96 h after injection, highest amounts of XTEN864-anxA5 were found in liver, spleen, and kidney. XTEN864-anxA5 was found to target the adventitia adjacent to atherosclerotic plaques. XTEN864-anxA5 is a long-circulating fusion protein that can be efficiently produced in E. coli and potentially circulates in humans for several days, making it a promising therapeutic drug.
- Published
- 2021
- Full Text
- View/download PDF